Economics & Value

Acute Myeloid Leukemia Treatment Episodes Linked to Significant Economic Burden

Chase Doyle

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Value-Based Care

Atlanta, GA—A retrospective analysis of a large commercial payer database has demonstrated a link between various treatment episodes of acute myeloid leukemia and substantial economic burden. According to data presented at ASH 2017, healthcare resource use and direct healthcare costs were associated with high-intensity chemotherapy induction, hematopoietic stem-cell transplantation (HSCT), and episodes of relapsed or refractory disease in a US commercially insured population. [ Read More ]

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Chase Doyle

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Multiple Myeloma, Value-Based Care

Atlanta, GA—A recent analysis of a commercial claims database suggests that oral therapy for multiple myeloma may help decrease the economic burden for patients and healthcare systems. According to data presented at ASH 2017, patients with multiple myeloma who received injectable therapy used significantly more disability benefits and incurred higher productivity costs than patients who received oral medications. [ Read More ]

Proactive Symptom Self-Reporting Extends Survival in Patients with Metastatic Cancer

Phoebe Starr

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Value-Based Care

Chicago, IL—The use of an online tool to self-report symptoms during treatment for metastatic cancer extended survival by 5 months compared with usual care according to a study presented at ASCO 2017. In addition, online self-reporting of symptoms improved quality of life (QOL) and reduced emergency department visits and hospitalizations versus usual care. [ Read More ]